Context matters in CAR T cell tonic signaling
- 10 May 2021
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 27 (5), 763-764
- https://doi.org/10.1038/s41591-021-01340-7
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cellsNature Medicine, 2021
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaThe New England Journal of Medicine, 2021
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design studyThe Lancet, 2020
- Chimeric Antigen Receptor T Cells in Refractory B-Cell LymphomasThe New England Journal of Medicine, 2017
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaThe New England Journal of Medicine, 2017
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapyNature Medicine, 2017
- Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane DomainsMolecular Therapy, 2017
- The Principles of Engineering Immune Cells to Treat CancerCell, 2017
- The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive forIn VivoAntitumor ActivityCancer Immunology Research, 2015
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In VivoMolecular Therapy, 2009